Worldwide trends and shortcomings in the treatment of hypertension

American Journal of Hypertension

Volumn 13, Issue 5 II SUPPL., 2000, Pages

  Julius, Stevo ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Aggressive antihypertensive treatment; Hypertension; JNC VI

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; AWARENESS; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG QUALITY; HEALTH CARE AVAILABILITY; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HYPERTENSION; PHYSICIAN ATTITUDE; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0034126046     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(00)00273-9     Document Type: Article

References (22)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-1034.
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-1152.
3. National High Blood Pressure Education Program: National High Blood Pressure Education Program program description. Available at:http://www.nhlbi.nih-.gov/about/nhbpep/nhbp_pd.htm. Accessed August 11, 1999.
4. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-69.
5. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
6. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-183.
7. Colhoun HM, Dong W, Poulter NR: Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998;16:747-752.
8. Gyarfas I: Control of hypertension in the population. Strategies in affluent and developing countries. Clin Exp Hypertens 1996;18:387-397.
9. Chockalingam A, Fodor JG: Treatment of raised blood pressure in the population. The Canadian experience. Am J Hypertens 1998;11(6 pt 1):747-749.
10. Chamontin B, Poggi L, Lang T, Ménard J, Chevalier H, Gallois H, Crémier O: Prevalence, treatment, and control of hypertension in the French population. Data from a survey on high blood pressure in general practice, 1994. Am J Hypertens 1998;11(6 pt 1):759-762.
11. Faulhaber H-D, Luft FC: Treatment of high blood pressure in Germany. Am J Hypertens 1998;11(6 pt 1):750-753.
12. Avanzini F, Alli C, Colombo P, Corsetti A, Colombo F, Tognoni G: Control of hypertension in Italy: results of the "Study on Antihypertensive Treatment in General Practice (STAP)". Physicians taking part in STAP. G Ital Cardiol 1998;28:760-766.
13. Banegas JR, Rodríguez-Artalejo F, de la Cruz Troca JJ, Guallar-Castillón P, del Rey Calero J: Blood pressure in Spain. Distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension 1998;32:998-1002.
14. Haynes RB: A critical review of the "determinants" of patient compliance with therapeutic regimens, in Sackett DL, Haynes RB (eds): Compliance with Therapeutic Regimens. The Johns Hopkins University Press, Baltimore, MD, 1974, pp 26-39.
15. Bloom BS: Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-681.
16. Hansson L, for the HOT Study Group: The Hypertension Optimal Treatment Study (the HOT Study). Blood Press 1993;2:62-68.
17. Kassirer JP: Doctor discontent (editorial). N Engl J Med 1998;339:1543-1545.
18. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762.
19. Hansson L: The Hypertension Optimal Treatment study and the importance of lowering blood pressure. J Hypertens 1999;17(suppl 1):S9-S13.
20. Opie LH: Principles of combination therapy for hypertension: what we learn from the HOT and other studies - a personal point of view. Cardiovasc Drugs Ther 1998;12:425-429.
21. Chalmers J: Hypertension Optimal Treatment (HOT) study: a brilliant concept, but a qualified success. J Hypertens 1998;16:1403-1405.
22. Diovan® (valsartan) Capsules, in Physicians' Desk Reference. 53rd ed. Medical Economics Co, Montvale, NJ, 1999, pp 2013-2015.